Zobrazeno 1 - 10
of 12
pro vyhledávání: '"H R, Mäcke"'
Publikováno v:
Polyhedron. 18:3243-3251
This contribution presents a selection of results obtained using spectrophotometric titrations and subsequent second-order global analysis of the data. For several reasons the investigated equilibria present particular challenges to traditional analy
Publikováno v:
Zeitschrift f�r anorganische und allgemeine Chemie. 621:854-860
Ausgehend von [MOCl4]−-Komplexen werden mit dem vierzahnigen Amin-Phenolato-Liganden N,N-Bis(2-hydroxybenzyl)-1,3-diamino-2-4-nitrobenzyl)propan (H2L1) Rhenium(V)- und Technetium(V)-Chelate hergestellt und strukturell charakterisiert. Es entstehen
Autor:
Marcel Maeder, H. R. Mäcke
Publikováno v:
Inorganic Chemistry. 33:3135-3140
The cobalt(II)complex (papd)Co II (H 2 O) 2+ (papd=1,5,8,11,15-pentaazapentadecane) reacts with molecular oxygen to form a μ-peroxo complex in the traditional Wilkins reaction scheme (k 1 = 1.4×10 -7 M -1 s -1 , k -1 =0.65 s -1 , k 2 =1.210 7 M -1
Publikováno v:
Praxis. 88(31-32)
Current concepts for the treatment of somatostatin receptor positive tumours have not been very motivating up to now. A promising alternative could be the new peptidic vector DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC) recently developed in Basel. It may b
Publikováno v:
Cancer research. 59(15)
Octreotide is a somatostatin analogue that is widely used for cancer therapy and tumor imaging. Its efficacy in tumors depends mainly on the expression of the somatostatin receptor type 2 (sst 2). Desensitization and down-regulation of sst 2 after ag
Autor:
A, Merlo, O, Hausmann, M, Wasner, P, Steiner, A, Otte, E, Jermann, P, Freitag, J C, Reubi, J, Müller-Brand, O, Gratzl, H R, Mäcke
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(5)
Human gliomas, especially of low-grade type, have been shown to express high-affinity somatostatin receptor type 2 (J-C. Reubi et al., Am. J. Pathol, 134: 337-344, 1989). We enrolled seven low-grade and four anaplastic glioma patients in a pilot stud
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(5)
Scintigraphy with [111In-diethylenetriamine pentaacetic acid0-D-Phe1]-octreotide (DTPAOC) is used to demonstrate neuroendocrine and other somatostatin-receptor-positive tumors. Despite encouraging results, this 111In-labeled compound is not well suit
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
Autor:
M, de Jong, W A, Breeman, W H, Bakker, P P, Kooij, B F, Bernard, L J, Hofland, T J, Visser, A, Srinivasan, M A, Schmidt, J L, Erion, J E, Bugaj, H R, Mäcke, E P, Krenning
Publikováno v:
Cancer research. 58(3)
We evaluated the following (111)In-labeled somatostatin (SS) analogues (diethylenetriaminepentaacetic acid, DTPA; tetraazacyclododecanetetraacetic acid, DOTA): [DTPA0]octreotide, [DTPA0,Tyr3]octreotide, [DTPA0,D-Tyr1]octreotide, [DTPA0,Tyr3]octreotat
Autor:
M, De Jong, W H, Bakker, W A, Breeman, B F, Bernard, L J, Hofland, T J, Visser, A, Srinivasan, M, Schmidt, M, Béhé, H R, Mäcke, E P, Krenning
Publikováno v:
International journal of cancer. 75(3)
We have evaluated the potential usefulness of radiolabelled [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide as radiopharmaceuticals for somatostatin receptor-targeted scintigraphy and radiotherapy. In vitro somatostatin receptor binding and in vivo
Autor:
I, Novak-Hofer, H P, Amstutz, H R, Mäcke, R, Schwarzbach, K, Zimmermann, J J, Morgenthaler, P A, Schubiger
Publikováno v:
Cancer research. 55(1)
Monoclonal antibody chCE7, an internalizing neuroblastoma-specific chimeric antibody, was derivatized with the macrocyclic amine ligand 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)-methyl] benzoic acid tetrahydrochloride and labeled with the potential th